# A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma

> **NCT03310567** · PHASE2 · WITHDRAWN · sponsor: **Fox Chase Cancer Center**

## Conditions studied

- Recurrent/ Metastatic Endometrial Carcinoma

## Interventions

- **DRUG:** Epacadostat + pembrolizumab

## Key facts

- **NCT ID:** NCT03310567
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-09
- **Primary completion:** 2018-09-10
- **Final completion:** 2018-09-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsors pulled out of the study
- **Last updated:** 2018-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03310567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03310567, "A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03310567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*